Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER RIGHT
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
1.00 · RIGHT
ML v2 (DistilBERT)
0.000 · CENTER
Ensemble
0.500 · CENTER RIGHT
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.054
2,788 articles tracked
7-day bias trend
LcenterR
Article Excerpt
The first‑in‑class antibody program is designed to selectively target pathogenic cells, with the potential to deliver deeper and more durable disease control than current therapies. The agreement strengthens Boehringer Ingelheim’s growing immunology pipeline and builds on other recent research partnership announcements. Ingelheim, Germany and Waltham, Mass., U.S., May X, 2026 – Boehringer Ingelheim and Immunitas...
Read full article at Montreal Gazette ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
quick v1
May 12, 2026